Comparative Pharmacology
Head-to-head clinical analysis: TRIOSTAT versus UNITHROID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIOSTAT versus UNITHROID.
TRIOSTAT vs UNITHROID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
Synthetic T4 (levothyroxine) is converted to T3, which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 4-6 weeks based on TSH; typical maintenance: 75-150 mcg orally once daily; maximum dose up to 300 mcg daily in severe hypothyroidism.
None Documented
None Documented
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
6-7 days for L-thyroxine (T4) in euthyroid patients; prolonged to 9-10 days in hypothyroidism, shortened to 3-4 days in hyperthyroidism. Clinical context: once-daily dosing achieves steady state in 6-8 weeks.
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Renal (approx. 20-40% as unchanged drug and glucuronide conjugates); fecal (minor, via bile).
Category C
Category C
Thyroid Hormone
Thyroid Hormone